Nykredit A S Invests $3.42 Million in Zimmer Biomet Holdings, Inc. $ZBH

Nykredit A S acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 39,716 shares of the medical equipment provider’s stock, valued at approximately $3,419,000.

Other large investors also recently bought and sold shares of the company. DV Equities LLC purchased a new stake in Zimmer Biomet during the fourth quarter worth $25,000. Tacita Capital Inc purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at $26,000. Ancora Advisors LLC purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at $29,000. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet in the 4th quarter worth $30,000. Finally, Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet in the 4th quarter worth $31,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.1%

NYSE ZBH opened at $97.94 on Monday. The company has a fifty day simple moving average of $94.82 and a two-hundred day simple moving average of $91.61. The stock has a market cap of $18.68 billion, a P/E ratio of 23.83, a P/E/G ratio of 1.85 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $106.88. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is currently 23.36%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Citigroup decreased their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. BMO Capital Markets restated a “market perform” rating and issued a $96.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.